<DOC>
	<DOCNO>NCT02622932</DOCNO>
	<brief_summary>The purpose study Investigate Absorption , Metabolism Excretion [ 14C ] Anlotinib Patients With Advanced Cancer patient .</brief_summary>
	<brief_title>Study Investigate Absorption , Metabolism Excretion 14C Anlotinib Patients With Advanced Cancer Patients</brief_title>
	<detailed_description />
	<criteria>sign date informed consent histologically cytologically confirm diagnosis advance solid tumor ( include RCC、NSCLC、STS CRC ) fail treatment line 1 2 ECOG PS:01 , Life expectancy 3 month main organ function normal prior treatment Anlotinib Allergic drug formulation ingredient subject gastrointestinal tract , liver kidney disease affect drug absorption metabolism CTCAE ( 4.0 ) Grade 1 high nonremission toxicity induce previous treatment patient pleural effusion ascites , cause respiratory syndrome ( CTCAE Grade 2 high dyspnea [ Grade 2 dyspnea refers Shortness breath small amount activity , affect Instrumental activity daily life ] ) patient underwent major surgical treatment，open biopsy significant traumatic injury within 28 day prior assignment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>